Thermo Fisher launches biomarker discovery grant program; Metamark rolls out prostate cancer prognosis test;

> Thermo Fisher Scientific ($TMO) said it will fast-track 12 research teams' gene-expression profiling projects focused on biomarker discovery by way of a new grant program. Release

> Arizona's Global Cancer Diagnostics is launching a $99 diagnostic test designed to enable the early detection of lung cancer. Release

> Illumina ($ILMN) will partner with genetic screening and diagnostics company Reprogenetics on in vitro fertilization gene-sequencing/diagnostics development. Story

> Tymora Analytical Operations in Indiana is moving ahead with a new federal grant to study blood plasma for biomarkers that can be a sign of various diseases. Story

> Massachusetts' Metamark has rolled out ProMark, a new protein-based biopsy test designed to give a more accurate prognosis for men diagnosed with prostate cancer. Release

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.